Barbaro G,Barbarini G. HIV infection and cancer in the era of higllly active antirelroviral therapy[J]. Oncol Rep,2007,17(5):1121.
[3]
Roth W K. Cellular and molecular featurs of HIV-addociated Kaposi\'s sarcoma[J].AIDS,1992,6:895.
[4]
Cooley T,Henry D,Tonda M,et al.A randomized,double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi\'s sarcoma[J].Oncologist,2007,12(1):114.
[5]
Krause J.AIDS-related non-Hodgkin\'s lymphomas[J]. Microscopy Res Technique,2005,68(3/4):168.
[6]
Knowles D M. Etiology and pathogenesis of AIDS-related non-Hodgkin\'s lymphoma[J].Hematol Oncol Clin North Am,2003,17(3): 785.
Chia-Ching Wang,Jorge J,Castillo. Patients with HIV-associated lymphomast should be treated by HIV oncologists in settings where they can benefit from research protocols[J].Manage HIV-Assoc Lymphomas,2011,94(1): 4.
[9]
徐航娣,周韧. AIDS 伴发的淋巴瘤的研究进展[J].国际病理学与临床杂志,2006,26(3): 222.
[10]
Oriol A,Ribera J M,Bergua J,et al. High-dose chemotherapy and immunothempy in adult Burkitt lymphoma comparison of results in human immunodeficiency virus-infected and noninfected patients[J].Cancer,2008,113(1): 117.
[11]
Ribera J M,Oriol A,Morgades M,et al. Safety and efficacy of cyclophosphamide,adriamycin,vincristine,prednisone and rituximab in patients with human immunodeficiency virus-asseciated diffuse large B-cell lymphoma: results of a phase II trial[J].Br J Haematol,2008,140(4): 411.
Vaccher E,Spina M,di Genaro G,et al. Concomitant cyclophosphamide,doxorubicin,vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related non-Hodgkin\'s lymphoma[J]. Cancer,2001,91(1): 155.
[15]
Little R F,Pittaluga S,Grant N,et al. Highly effective treatment of acquired inmmunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology[J].Blood,2003,101(12): 4653.
[16]
Chia-Ching Wang,Jorge J,Castillo. Patients with HIV-associated lymphomas should be treated by HIV oncologists in settings where they can benefit from research protocols[J].Manage HIV-Assoc Lymphomas,2011,94(1): 4.
[17]
Sparano J A. HIV-associated lymphoma: the evidence for treating aggressively but withcaution[J].Curr Opin Oncol,2007,19(5): 458.
[18]
Lim S T,Karim R,Nathwani B N,et al. AIDS-related Burkitt\'s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiret-roviral therapy (HAART) and HAART eras[J].J Clin Oncol,2005,23(19): 4430.
[19]
Perkins A S,Friedberg J W. Burkitt lymphoma in adult[M]. Hematol Am Soc Hematol Educ Program,2008: 341.
[20]
CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults [EB/OL]. [1992-12-18].http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm.
[21]
World Health Organization.IARC working group on the evaluation of carcinogenic risks to humans. Human immunodeficiency viruses and human T2cell lymphotropic viruses. IARC monographs on the evaluation of carcinogenic risks to humans[M]. Lyon:IARC,1996.
[22]
Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS2 related tumors in developed and developing countries[J]. Eur J Cancer, 2001, 37:1188.
[23]
Shrivastava S K,Engineer R,Rajadhyaksha S,et al.HIV infection and invasive cervical cancers, treatment with radiation therapy: toxicity and outcome[J].Radiother Oncol, 2005,74(1):31.